Lantern Pharma(LTRN.US)

Last Updated 19:00:00 ET
longbridge loading

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

PUBT·
US
LTRN
+0.67%
US
XLV
+1.34%
US
IHE
+0.87%
PUBT·
US
LTRN
+0.67%
US
XLV
+1.34%
US
IHE
+0.87%

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC | LTRN Stock News

StockTitan·
US
LTRN
+0.67%
US
ARKG
-0.71%
US
VHT
+1.22%
StockTitan·
US
LTRN
+0.67%
US
ARKG
-0.71%
US
VHT
+1.22%

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga_article·
US
GOSS
+8.41%
US
LTRN
+0.67%
US
AIM
-17.89%
benzinga_article·
US
GOSS
+8.41%
US
LTRN
+0.67%
US
AIM
-17.89%

Lantern Pharma | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.3

Earnings Watch·
US
LTRN
+0.67%
Earnings Watch·
US
LTRN
+0.67%

Lantern Pharma raises capital, plans AI platform spinoff

Tip Ranks·
US
LTRN
+0.67%
US
IBB
+0.43%
US
FBT
+0.62%
Tip Ranks·
US
LTRN
+0.67%
US
IBB
+0.43%
US
FBT
+0.62%

Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw

TradingView·
US
LTRN
+0.67%
TradingView·
US
LTRN
+0.67%

Pre-market hot trades in US stocks: Lantern Pharma up 7.17% in pre-market; AST SpaceMobile up 3.30% in pre-market

Price Alert·
US
LTRN
+0.67%
US
ASTS
-4.80%
Price Alert·
US
LTRN
+0.67%
US
ASTS
-4.80%

Lantern Pharma shares are trading higher after Lantern Pharma announced up to a $9.25 million direct offering with existing shareholders.

benzinga_article·
US
LTRN
+0.67%
US
XBI
-0.44%
US
BBH
+0.83%
benzinga_article·
US
LTRN
+0.67%
US
XBI
-0.44%
US
BBH
+0.83%
© 2026 Longbridge｜Disclaimer